Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT‐C trial

Backgroud  The impact of virologic response on hepatic function has not been previously defined.

[1]  Edward A Belongia,et al.  National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.

[2]  J. Hoefs,et al.  The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti‐viral Long‐term Treatment against Cirrhosis Trial 1 , 2008, Alimentary pharmacology & therapeutics.

[3]  M. Manns,et al.  Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis , 2007, Annals of Internal Medicine.

[4]  Yoshiyuki Suzuki,et al.  Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. , 2007, Journal of medical virology.

[5]  J. Hoefs,et al.  Portal‐systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt , 2007, Alimentary pharmacology & therapeutics.

[6]  Yoshiyuki Suzuki,et al.  Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C , 2007, Journal of medical virology.

[7]  I. Sheen,et al.  Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386‐patient study from Taiwan , 2007, Alimentary pharmacology & therapeutics.

[8]  A. Mangia,et al.  Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.

[9]  William M. Lee,et al.  Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT‐C trial , 2006, Hepatology.

[10]  C. Ripoll,et al.  Antiviral Therapy Decreases Hepatic Venous Pressure Gradient in Patients with Chronic Hepatitis C and Advanced Fibrosis , 2006, The American Journal of Gastroenterology.

[11]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[12]  Y. Lacasse,et al.  From the authors , 2005, European Respiratory Journal.

[13]  G. Everson,et al.  Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy , 2005, Hepatology.

[14]  H. El‐Serag,et al.  Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.

[15]  William M. Lee,et al.  Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. , 2004, Controlled clinical trials.

[16]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[17]  P. Marcellin,et al.  Effect of peginterferon alfa‐2a on liver histology in chronic hepatitis C: A meta‐analysis of individual patient data , 2004, Hepatology.

[18]  N. Kurata,et al.  How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? , 2003, Journal of clinical pharmacy and therapeutics.

[19]  J. Hoofnagle,et al.  National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002 , 2002, Gastroenterology.

[20]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[21]  M. Droździk,et al.  Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis , 2002, European Journal of Drug Metabolism and Pharmacokinetics.

[22]  N. Méndez-Sánchez.  [Epidemiology of hepatitis C]. , 2002, Revista de gastroenterologia de Mexico.

[23]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[24]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[25]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[26]  K. Ishak,et al.  Long‐term mortality and morbidity of transfusion‐associated non‐A, non‐B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study , 2001, Hepatology.

[27]  J. Wong,et al.  Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.

[28]  E. Hahn,et al.  Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy. , 2000, World journal of gastroenterology.

[29]  H. Margolis,et al.  The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States , 2000, Hepatology.

[30]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[31]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[32]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[33]  Dafydd Gibbon,et al.  1 User’s guide , 1998 .

[34]  Eugene R. Schiff,et al.  National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.

[35]  U. Spengler,et al.  The low‐dose monoethylglycinexylidide test: Assessment of liver function with fewer side effects , 1997, Hepatology.

[36]  G. Everson,et al.  Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[37]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[38]  A. Berger.  FUNDAMENTALS OF BIOSTATISTICS , 1969 .

[39]  N. Afdhal.  The natural history of hepatitis C. , 2004, Seminars in liver disease.

[40]  H J Alter,et al.  Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.